Literature DB >> 22855500

Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry.

Jingyu Diao1, Homer Pantua, Hai Ngu, Laszlo Komuves, Lauri Diehl, Gabriele Schaefer, Sharookh B Kapadia.   

Abstract

While epidermal growth factor receptor (EGFR) has been shown to be important in the entry process for multiple viruses, including hepatitis C virus (HCV), the molecular mechanisms by which EGFR facilitates HCV entry are not well understood. Using the infectious cell culture HCV model (HCVcc), we demonstrate that the binding of HCVcc particles to human hepatocyte cells induces EGFR activation that is dependent on interactions between HCV and CD81 but not claudin 1. EGFR activation can also be induced by antibody mediated cross-linking of CD81. In addition, EGFR ligands that enhance the kinetics of HCV entry induce EGFR internalization and colocalization with CD81. While EGFR kinase inhibitors inhibit HCV infection primarily by preventing EGFR endocytosis, antibodies that block EGFR ligand binding or inhibitors of EGFR downstream signaling have no effect on HCV entry. These data demonstrate that EGFR internalization is critical for HCV entry and identify a hitherto-unknown association between CD81 and EGFR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855500      PMCID: PMC3457153          DOI: 10.1128/JVI.00750-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.

Authors:  Eric H Raabe; Kah Suan Lim; Julia M Kim; Alan Meeker; Xing-Gang Mao; Guido Nikkhah; Jarek Maciaczyk; Ulf Kahlert; Deepali Jain; Eli Bar; Kenneth J Cohen; Charles G Eberhart
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

3.  Efficient production of antibodies against a mammalian integral membrane protein by phage display.

Authors:  Isidro Hötzel; Vicki Chiang; Jingyu Diao; Homer Pantua; Henry R Maun; Sharookh B Kapadia
Journal:  Protein Eng Des Sel       Date:  2011-08-02       Impact factor: 1.650

4.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.

Authors:  Gabriele Schaefer; Lauric Haber; Lisa M Crocker; Steven Shia; Lily Shao; Donald Dowbenko; Klara Totpal; Anne Wong; Chingwei V Lee; Scott Stawicki; Robyn Clark; Carter Fields; Gail D Lewis Phillips; Rodney A Prell; Dimitry M Danilenko; Yvonne Franke; Jean-Philippe Stephan; Jiyoung Hwang; Yan Wu; Jenny Bostrom; Mark X Sliwkowski; Germaine Fuh; Charles Eigenbrot
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

5.  Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion.

Authors:  Nishi R Sharma; Guaniri Mateu; Marlene Dreux; Arash Grakoui; François-Loïc Cosset; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

Review 6.  Cetuximab in the treatment of patients with colorectal cancer.

Authors:  Christopher R Garrett; Cathy Eng
Journal:  Expert Opin Biol Ther       Date:  2011-05-11       Impact factor: 4.388

7.  The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells.

Authors:  Thorsten Eierhoff; Eike R Hrincius; Ursula Rescher; Stephan Ludwig; Christina Ehrhardt
Journal:  PLoS Pathog       Date:  2010-09-09       Impact factor: 6.823

8.  Hepatitis C virus induces CD81 and claudin-1 endocytosis.

Authors:  Michelle J Farquhar; Ke Hu; Helen J Harris; Christopher Davis; Claire L Brimacombe; Sarah J Fletcher; Thomas F Baumert; Joshua Z Rappoport; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 9.  Hepatitis C virus entry and the tetraspanin CD81.

Authors:  Michelle J Farquhar; Helen J Harris; Jane A McKeating
Journal:  Biochem Soc Trans       Date:  2011-04       Impact factor: 5.407

10.  Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

Authors:  Bruno Sainz; Naina Barretto; Danyelle N Martin; Nobuhiko Hiraga; Michio Imamura; Snawar Hussain; Katherine A Marsh; Xuemei Yu; Kazuaki Chayama; Waddah A Alrefai; Susan L Uprichard
Journal:  Nat Med       Date:  2012-01-08       Impact factor: 53.440

View more
  62 in total

Review 1.  The ins and outs of hepatitis C virus entry and assembly.

Authors:  Brett D Lindenbach; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2013-09-10       Impact factor: 60.633

Review 2.  Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs.

Authors:  Stanford Schor; Shirit Einav
Journal:  DNA Cell Biol       Date:  2017-11-17       Impact factor: 3.311

3.  The missing pieces of the HCV entry puzzle.

Authors:  Sarah C Ogden; Hengli Tang
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

4.  Hepatitis C Virus E2 Envelope Glycoprotein Induces an Immunoregulatory Phenotype in Macrophages.

Authors:  Young-Chan Kwon; Keith Meyer; Guangyong Peng; Soumya Chatterjee; Daniel F Hoft; Ranjit Ray
Journal:  Hepatology       Date:  2018-05-24       Impact factor: 17.425

5.  Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study.

Authors:  Jessica L Mueller; Lindsay Y King; Kara B Johnson; Tian Gao; Lauren D Nephew; Darshan Kothari; Mary Ann Simpson; Hui Zheng; Lan Wei; Kathleen E Corey; Joseph Misdraji; Joon Hyoek Lee; M Valerie Lin; Neliswa A Gogela; Bryan C Fuchs; Kenneth K Tanabe; Fredric D Gordon; Michael P Curry; Raymond T Chung
Journal:  Clin Transplant       Date:  2016-03-01       Impact factor: 2.863

6.  Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection.

Authors:  Terence N Bukong; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2013-09-17       Impact factor: 17.425

Review 7.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

8.  Epidermal Growth Factor Receptor and Abl2 Kinase Regulate Distinct Steps of Human Papillomavirus 16 Endocytosis.

Authors:  Carina Bannach; Pia Brinkert; Lena Kühling; Lilo Greune; M Alexander Schmidt; Mario Schelhaas
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

9.  Porcine Epidemic Diarrhea Virus-Induced Epidermal Growth Factor Receptor Activation Impairs the Antiviral Activity of Type I Interferon.

Authors:  Lijun Yang; Jiayu Xu; Longjun Guo; Taijie Guo; Lu Zhang; Li Feng; Hongyan Chen; Yue Wang
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

Review 10.  Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

Authors:  Ozan Yazici; Mehmet Ali Nahit Sendur; Sercan Aksoy
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.